<DOC>
	<DOCNO>NCT01332019</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability peginterferon beta-1a ( BIIB017 ) participant originally treat Study 105MS301 ( NCT00906399 ) continue peginterferon beta-1a treatment . The secondary objective study describe long-term multiple sclerosis ( MS ) outcomes participant originally treat Study 105MS301 ( NCT00906399 ) continue peginterferon beta-1a treatment .</brief_summary>
	<brief_title>Long-Term Safety Efficacy Study Peginterferon Beta-1a</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Must complete study treatment visit schedule Week 96 Study 105MS301 ( NCT00906399 ) . Key Subjects exceed 6 week since completion Week 96 visit Study 105MS301 ( NCT00906399 ) . Subjects clinically significant laboratory abnormality , malignancy , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease Pregnant nursing woman . NOTE : Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Subcutaneous</keyword>
	<keyword>Extension</keyword>
	<keyword>Interferon</keyword>
	<keyword>MS</keyword>
	<keyword>PEGylated</keyword>
	<keyword>Injectable</keyword>
	<keyword>SC</keyword>
	<keyword>PEG</keyword>
	<keyword>peginterferon beta-1a</keyword>
	<keyword>Relapsing</keyword>
</DOC>